Blockchain Registration Transaction Record

BioCorRx Appoints Louis Lucido as Board Chair in Leadership Transition

BioCorRx announces Louis Lucido as new Board Chair, succeeding Kent Emry. Learn about their addiction and obesity treatment programs, including LUCEMYRA® and UnCraveRx®.

This leadership transition at BioCorRx matters because the company is at the forefront of addressing some of today's most pressing public health crises: addiction and obesity. With substance use disorders and obesity affecting millions globally—over 16.6 million have used methamphetamine, and an estimated 1 billion people are obese—effective treatments are urgently needed. BioCorRx's programs, like Beat Addiction Recovery and UnCraveRx®, offer innovative, integrated approaches that combine medication with behavioral support, potentially improving outcomes for patients. The appointment of Louis Lucido, with his extensive experience, could enhance the company's strategic direction, accelerating the development and availability of treatments such as LUCEMYRA® for opioid withdrawal and BICX104 for addiction. This impacts readers by highlighting advancements in healthcare that may offer new hope for individuals and families struggling with these conditions, while also underscoring the importance of corporate governance in driving medical innovation.